Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Autor: Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, Chi-Yi Chen, Ching-Chu Lo, Kuo-Chih Tseng, Pei-Yuan Su, Wei-Yu Kao, Ming-Chang Tsai, Hung-Da Tung, Hao-Tsai Cheng, Fu-Jen Lee, Chia-Sheng Huang, Ke-Jhang Huang, Yu-Lueng Shih, Sheng-Shun Yang, Jo-Hsuan Wu, Hsueh-Chou Lai, Yu-Jen Fang, Po-Yueh Chen, Jow-Jyh Hwang, Chi-Wei Tseng, Wei-Wen Su, Chun-Chao Chang, Pei-Lun Lee, Jyh-Jou Chen, Chi-Yang Chang, Tsai‐Yuan Hsieh, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao
Rok vydání: 2023
Předmět:
Zdroj: Hepatology International. 17:291-302
ISSN: 1936-0541
1936-0533
DOI: 10.1007/s12072-022-10475-9
Popis: Background Real-world data are scarce about the effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian patients with hepatitis C virus (HCV) infection who previously received NS5A direct-acting antivirals (DAAs). We conducted a multicenter study to assess the performance of SOF/VEL/VOX in patients who were not responsive to prior NS5A inhibitors in Taiwan. Methods Between September 2021 and May 2022, 107 patients who failed NS5A inhibitor-containing DAAs with SOF/VEL/VOX salvage therapy for 12 weeks were included at 16 academic centers. The sustained virologic response at off-treatment week 12 (SVR12) was assessed in the evaluable (EP) and per-protocol (PP) populations. The safety profiles were also reported. Results All patients completed 12 weeks of treatment and achieved an end-of-treatment virologic response. The SVR12 rates were 97.2% (95% confidence interval (CI): 92.1%-99.0%) and 100% (95% CI: 96.4%-100%) in EP and PP populations. Three (2.8%) patients were lost to off-treatment follow-up and did not meet SVR12 in the EP population. No baseline factors predicted SVR12. Two (1.9%) not-fatal serious adverse events (AE) occurred, but unrelated to SOF/VEL/VOX. Sixteen (15.0%) had grade 2 total bilirubin elevation, and three (2.8%) had grade 2 alanine transaminase (ALT) elevation. Thirteen (81.3%) of the 16 patients with grade 2 total bilirubin elevation had unconjugated hyperbilirubinemia. The estimated glomerular filtration rates (eGFR) were comparable between baseline and SVR12, regardless of baseline renal reserve. Conclusions SOF/VEL/VOX is highly efficacious and well-tolerated for East Asian HCV patients previously treated with NS5A inhibitor-containing DAAs.
Databáze: OpenAIRE
Externí odkaz: